ZYME

Companies
NASDAQ
Zymeworks Inc.
Health Care
Price Chart
Overview

About ZYME

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Market Cap
$641.3M
Volume
9.5M
Avg. Volume
9.7M
P/E Ratio
-5.8988094
Dividend Yield
0.00%
Employees
306.0

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
0.94
Moderate Correlation
Volatility
High (0.50)
Relative to market

Macro Factor Sensitivities

Interest Rates
Medium Sensitivity
Inflation
Low Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for ZYME.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, ZYME shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$641.3M
Volume9.5M
P/E Ratio-5.90
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
March 6, 2025

PortfolioPilot Analysis

Get AI-powered insights on how ZYME fits into your investment strategy and portfolio diversification.

Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025